Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1901 to 1950 of 3008 results for all

  1. Ultrasound-guided regional nerve block (HTG179)

    Evidence-based recommendations on ultrasound-guided regional nerve block. This involves using ultrasound guidance to position needles that deliver local anaesthetic in the correct place next to the nerves.

  2. Macular translocation with 360° retinotomy for wet age-related macular degeneration (HTG216)

    Evidence-based recommendations on macular translocation with 360° retinotomy for wet age-related macular degeneration. This involves cutting and moving the macula on to a nearby healthier area of the choroid layer.

  3. QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography (HTG571)

    Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.

  4. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

  5. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

  6. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)

    Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.

  7. Attention deficit hyperactivity disorder (QS39)

    This quality standard covers diagnosing and managing attention deficit hyperactivity disorder (ADHD) in adults, young people and children (aged 3 and over). It describes high-quality care in priority areas for improvement.

  8. Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults.

  9. Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)

    This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes

  10. Laparoscopic augmentation cystoplasty (including clam cystoplasty) (HTG207)

    Evidence-based recommendations on Laparoscopic augmentation cystoplasty (including clam cystoplasty). This involves sewing or stapling a tissue graft from a section of the small intestine (ileum), colon or other substitutes to the urinary bladder.

  11. UK licensing and technology appraisals

    NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.

  12. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

    Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.

  13. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

    Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.

  14. Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.

  15. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

  16. Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

    Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.

  17. Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (TA1039)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.

  18. PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)

    NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .

  19. NPi-200 for pupillary light reflex in critical care patients (MIB235)

    NICE has developed a medtech innovation briefing (MIB) on NPi-200 for pupillary light reflex in critical care patients .

  20. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

    Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

  21. Implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis (HTG366)

    Evidence-based recommendations on implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis.

  22. Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease (HTG395)

    Evidence-based recommendations on electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease. This involves applying low-energy electrical impulses to the sphincter to strengthen the muscle so that less reflux happens.

  23. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence

  24. DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography (HTG594)

    Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography.

  25. Non-Hodgkin's lymphoma: diagnosis and management (NG52)

    This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.

  26. Bronchiolitis in children: diagnosis and management (NG9)

    This guideline covers diagnosing and managing bronchiolitis in babies and children. It aims to help healthcare professionals diagnose bronchiolitis and identify if babies and children should be cared for at home or in hospital. It describes treatments and interventions that can be used to help with the symptoms of bronchiolitis.

  27. Tebentafusp for treating advanced uveal melanoma (TA1027)

    Evidence-based recommendations on tebentafusp (Kimmtrak) for treating uveal melanoma in adults.

  28. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input

  29. HumiGard for preventing inadvertent perioperative hypothermia (HTG428)

    Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia.

  30. Negative pressure wound therapy for the open abdomen (HTG321)

    Evidence-based recommendations on negative pressure wound therapy for the open abdomen. This involves using a small pump to remove infected material, stop fluid escaping and help the wound heal.

  31. Thrombin injections for pseudoaneurysms (HTG33)

    Evidence-based recommendations on thrombin injections for pseudoaneurysms. This involves injecting thrombin into the pseudoaneurysm. The aim is to form a small clot to plug the ‘hole’ in the artery.

  32. Extracorporeal shockwave therapy for refractory tennis elbow (HTG201)

    Evidence-based recommendations on extracorporeal shockwave therapy for refractory tennis elbow. This involves using a machine to deliver sound waves to the painful area to stimulate healing.

  33. Commercial access agreements

    The NICE commercial liaison team aim to reduce the workload for the NHS and frontline staff by making commercial agreements more straightforward.

  34. Fertility problems: assessment and treatment (NG257)

    This guideline covers diagnosing and treating health-related fertility problems. It aims to reduce variation in practice and improve how fertility problems are investigated and managed.

  35. Mobi-C for cervical disc replacement (MIB70)

    NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement

  36. Teduglutide for treating short bowel syndrome (TA804)

    Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.

  37. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

  38. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.

  39. Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)

    NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma

  40. Tivozanib for treating advanced renal cell carcinoma (TA512)

    Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

  41. Neon EEG electrode for EEG monitoring in newborns (MIB155)

    NICE has developed a medtech innovation briefing (MIB) on Neon EEG electrode for EEG monitoring in newborns .

  42. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

  43. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

  44. Hepatitis B (QS65)

    This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.

  45. Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction (HTG402)

    Evidence-based recommendations on angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction in adults. This involves using a device to improve blood flow to the penis.

  46. Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (HTG653)

    Evidence-based recommendations on transcutaneous electrical stimulation of the trigeminal nerve for ADHD. This involves a single-use electrode patch stuck to the forehead, which sends small electrical pulses through the skin during sleep.

  47. YAG laser vitreolysis for symptomatic vitreous floaters (HTG644)

    Evidence-based recommendations on YAG laser vitreolysis for symptomatic vitreous floaters. This involves a special type of laser (YAG) firing short pulses of energy into the floaters, to break them up (vitreolysis) and reduce sight disturbances.

  48. Laparoscopic cystectomy (HTG181)

    Evidence-based recommendations on laparoscopic cystectomy. This involves removing the bladder using small cuts in the abdomen (keyhole surgery).

  49. Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids (HTG277)

    Evidence-based recommendations on magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids. This involves using magnetic resonance imaging (MRI) to locate the fibroids and direct high-intensity ultrasound energy to destroy fibroid tissue.

  50. Percutaneous radiofrequency ablation for atrial fibrillation (HTG110)

    Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.